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http://www.biomedcentral.com/1471-2350/15/116RESEARCH ARTICLE Open AccessFamilial imbalance in 16p13.11 leads to a dosage
compensation rearrangement in an unaffected
carrier
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Roberto Rodríguez3, Elena Mansilla1,2, María Palomares1,2, Fernando Santos-Simarro1,2, Elena Vallespín1,2,
María Ángeles Mori1,2 and Pablo Lapunzina1,2Abstract
Background: We and others have previously reported that familial cytogenetic studies in apparently de novo
genomic imbalances may reveal complex or uncommon inheritance mechanisms.
Methods: A familial, combined genomic and cytogenetic approach was systematically applied to the parents of all
patients with unbalanced genome copy number changes.
Results: Discordant array-CGH and FISH results in the mother of a child with a prenatally detected 16p13.11 interstitial
microduplication disclosed a balanced uncommon rearrangement in this chromosomal region. Further dosage and
haplotype familial studies revealed that both the maternal grandfather and uncle had also the same 16p duplication as
the proband. Genomic compensation observed in the mother probably occurred as a consequence of interchromosomal
postzygotic nonallelic homologous recombination.
Conclusions: We emphasize that such a dualistic strategy is essential for the full characterization of genomic
rearrangements as well as for appropriate genetic counseling.
Keywords: 16p13.11 duplication, Gene dosage compensation, Homologous balanced rearrangement, Mitotic NAHRBackground
The combination of array-based comparative genomic
hybridization (aCGH) technology and subsequent parental
fluorescence in situ hybridization (FISH) analysis looking
for balanced parental rearrangements has revealed com-
plex or unusual genomic rearrangements that seem more
common than previously considered [1-3]. Recently, it
has been also demonstrated that parental submicroscopic
insertional translocations (ITs) underlie ~2.1% of the
apparently de novo interstitial pathogenic copy number
variations (CNVs) [4].
At the same time, the clinical use of aCGH has lead
to the detection of many CNVs, a number of them of
uncertain clinical relevance. Patients with 16p13.11* Correspondence: lfernandezg@salud.madrid.org
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unless otherwise stated.duplication and its reciprocal deletion have been previously
reported and are relatively common. However, whereas
the 16p13.11 deletion showed to be a pathogenic CNV,
the duplication was initially thought to be benign [5].
Other authors described an incomplete penetrance and/or
variable expressivity, the same duplication being found
both in mildly affected and unaffected relatives within
the same family [6,7]. Clinical features such as cognitive
impairment, behavioral disorders, congenital heart defects,
skeletal malformations and abnormal magnetic resonance
imaging (MRI) findings have been associated with CNVs
involving 16p13.11 [8].
In this report we describe a child with a brain malforma-
tion detected by prenatal ultrasound in which a prenatal
aCGH study identified a 1.78 Mb duplication at 16p13.11.
Further parental FISH analysis showed that the phenotyp-
ically normal mother was carrying an unusual apparently
balanced rearrangement between the two chromosomeal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the patient’s maternal grandfather and maternal uncle,
all three apparently phenotypically normal, were also
carriers of the same 16p duplication detected in the
proband.
Methods
Clinical report
Samples from the proband and his family were obtained
after informed consent. Ethical approval was obtained for
this study from the IRB at Hospital Universitario La Paz
in Madrid (HULP-CEIC-PI1207). Research was performed
in compliance with the Declaration of Helsinki.
The patient, a male, was the product of the third
pregnancy of a 34 year old woman. Both parents were
healthy, phenotypically normal and nonconsanguineous.
The first pregnancy ended in an elective termination
and the second resulted in a healthy boy. A prenatal
ultrasound at 28 weeks gestation revealed agenesis of
corpus callosum. Further examination at 37 weeks
showed two interhemispheric cysts along with corpus
callosum agenesis and colpocephaly. He was born at
40 weeks of gestation by spontaneous vaginal delivery.
At birth, weight was 3660 g (75–90th centile), length
52 cm (90th centile) and head circumference 36 cm
(90th centile). Perinatal period was uneventful and
Apgar scores were 9 and 10 at 5 and 10 minutes, respect-
ively. Renal ultrasound showed mild bilateral pelvicalyceal
dilatation.
Although initial marsupialisation of the cysts carried out
at 20 days of life showed some reduction in their volume,
subsequent increase in their size despite multiple drainage
interventions mandated the placement of a permanent
ventriculoperitoneal shunt at 10 months of age.
He was last seen in clinic aged 14 months, the brain
MRI showing a 50% reduction in cysts volume. At that
time, his developmental evaluation disclosed a normal
cognitive profile for age with a motor delay secondary to
left side hemiparesis.
His older brother was assessed in clinic aged 3, showing
at that time a normal phenotype, normal growth parame-
ters and a normal development for his age. The maternal
uncle and grandparents were not directly evaluated in the
genetics clinic, but were referred as normal by other family
members.
Genomic and cytogenetic studies
According to our workflow in prenatal samples with
two or more ecographic markers, aCGH was performed
in the patient and his parents, using a custom oligo-
nucleotide array (KaryoArray® v3.0, 8 × 60 K, Agilent
Technologies, Santa Clara, CA) as described previously [9].
This array has an average density of one probe per 9 Kb in
clinically relevant regions (microdeletion/microduplicationsyndromes, subtelomeric and pericentromeric regions)
and one probe per 175 Kb in other genomic regions
including 16p13.11 (backbone). Further versions of this
array will include this and other regions as they are
associated with clinical phenotypes.
Karyotyping and FISH were performed on cultured per-
ipheral blood lymphocytes. FISH studies were performed
using standard procedures applying probe NDE1-MYH11
mapping 16p13.11 (Agilent Technologies, Inc., Santa
Clara, CA).
Short tandem repeat (STR) markers segregation studies
were carried out in the family to confirm gene dosage
and to determine the parental origin of the rearranged
chromosomal material. Genomic DNA was obtained using
standard procedures from peripheral blood lymphocytes
in all family members (QIAGEN, Valencia, CA), and from
buccal swab in the mother (DNA Genotek, Kanata,
Canada). Three polymorphic markers mapping to region
16p13.11 (D16S3060: 15,860,105-15,860,300; D16S3127:
15,870,885-15871004; D16S405: 15,882,592-15,882,733;
hg19) and other nine markers located along chromo-
some 16 (D16S3070, D16S3088, D16S3024, D16S3079,
D16S3114, D16S500, D16S690, D16S753, D16S3043)
were analyzed.
Further studies to determine the presence of the gene
dosage alteration in other family members were also carried
out by Multiplex Ligation-dependent Probe Amplification
(MLPA) using SALSA P092-B3 probemix containing
probes for genes ABCC6 and ABCC1 in 16p13.11
(MRC-Holland, Amsterdam, The Netherlands).
Results
Array comparative genomic hybridization in the patient
revealed a gain of 1.78 Mb on 16p12.3-p13.11 (hg19,
chromosome 16: 15,111,247-16,895,894) (Figure 1a).
Genes included in this region are: PDXDC1, NTAN1,
RRN3, MPV17L, C16orf45, KIAA0430, MIR484, NDE1
(MIM 609449), MYH11 (MIM 160745), C16orf63, ABCC1,
ABCC6 (MIM 603234), NOMO3, PKD1P1. This finding
was interpreted as a CNV of uncertain significance since
this region had been reported to show copy number vari-
ation in individuals with no obvious phenotype, it contained
several MIM genes and there was an ongoing debate as to
the exact clinical significance of the CNV. Further aCGH
studies on both parents were normal (Figure 1d) thus the
duplication was initially considered an apparently de novo
event in the boy.
Duplication in the proband could have hardly been
detected in metaphase FISH studies, although retro-
spective re-evaluation of images noted a brighter signal
pattern on one homologue (Figure 1b). Further interphase
nuclei analysis with the same probe demonstrated actually
three signals, two of them located in close proximity
(Figure 1c). These findings supported the results of
Figure 1 aCGH and FISH results in the proband and the mother. a) Proband aCGH results showing 16p13.11 duplication. b-c) Proband FISH
results with probe NDE1-MYH11 (red) showing two signals on the metaphase chromosomes (b) and three signals on the interphase nucleus
(c). d) Mother aCGH results showing no 16p13.11 duplication. e-f) Mother FISH results with the same probe showing one signal on metaphase
chromosomes (e) and two signals on the interphase nucleus (f).
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amplification observed in the patient was located within
that same region. His karyotype was then described as:
ish dup(16)(p12.3p13.11)(NDE1-MYH11enh). nuc ish
16p13.11(NDE1-MYH11x3).
Discordant to the aCGH result, metaphase FISH ana-
lysis in the mother showed a deletion pattern, with only
one probe signal on one chromosome 16. This signal
was also brighter than usual, suggesting that two copies
of 16p13.11 were present on that chromosome (Figure 1e).
Further interphase nuclei FISH testing was then performed,
and two signals adjacent to one another were observed
(Figure 1f). Therefore, in combination with the aCGH
result, FISH findings were interpreted as a balanced inter-
chromosomal rearrangement at 16p12.3-p13.11, resulting
in one chromosome 16 with an interstitial deletion and the
other with an interstitial insertion. The karyotype of the
mother was described as follows: ish der(16)ins(16)(16;16)
(p1?2.3;p1?2.3p1?3.11)(NDE1-MYH11enh),der(16)ins(16)
(16;16)(p1?2.3;p1?2.3p1?3.11)(NDE1-MYH11-). nuc ish
16p13.11(NDE1-MYH11x2).Interpretation of the rearrangement in the mother and
its associated recurrence risk focused attention on the
proband’s elder brother. By means of MLPA, the same
results as in the proband were obtained, indicating that
both children had inherited the derivative maternal
chromosome 16 carrying two copies of 16p13.11. Thus,
their karyotypes were described as: ish der(16)ins(16)
(16;16)(p1?2.3;p1?2.3p1?3.11)(NDE1-MYH11enh)mat.
Surprisingly, further familial studies showed that both
the maternal grandfather and the maternal uncle also
carried the same duplication as the proband.
The analysis of three STR markers mapping within the
region delimited by aCGH supported previous gene
dosage results in the children, maternal grandfather,
and maternal uncle. In the mother, the grandpaternal
genotype was observed in two of the three markers.
However, all other informative markers (6) in chromo-
some 16 showed biparental inheritance. The same results
were obtained in DNA from buccal swab in the mother,
and they are consistent with a deletion of the maternal
allele of 16p13.11 (Figure 2).
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Figure 2 Pedigree chart showing haplotypes of 12 markers spanning chromosome 16. Markers D16S3060, D16S3127 and D16S405 are
located within the rearranged segment 16p13.11, which shows extra dosage in individuals I:1, II:1, II:3, III:1 and III:2. Colors indicate the
grandparental origin of the chromosomal material. Numbers designate the size in bp of the fragment including the marker.
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Only a few cases describing homologous balanced rear-
rangements have been reported so far. Most of them
occurred at 22q11.2 region [1-3], which is well known for
being rich in low copy repeats (LCRs). Most constitutional
translocations involving 22q11 share the same 22q11.2
breakpoint located within LCR-B, and these breakpoints
are usually located at the center of palindromic AT-rich
repeat sequences (PATRRs) [10]. Therefore, palindrome-
mediated translocations have been suggested as one of the
mechanisms for human chromosomal rearrangements.
The short arm of chromosome 16 has a similar structure
with over 10% of the euchromatic region being composed
of LCRs which promote non-allelic homologous recom-
bination (NAHR) [7,11,12].Haplotype analysis suggests two possible mechanisms
underlying the origin of the balanced rearrangement in
the proband’s mother. We can hypothesize that previous
to conception, a meiotic NAHR might have occurred in
the proband’s grandmother (we also cannot exclude the
possibility of a germline mosaicism) with the subsequent
transmission to the proband’s mother of the deleted
chromosome 16. A duplicated chromosome 16 would have
been transmitted by the proband’s grandfather. A second
and more likely mechanism is a mitotic NAHR between a
maternal and paternal chromatid within the first zygotic
divisions that would originate four chromatids: the two
recombination products (one with a triplication and the
other one with the reciprocal deletion) and two original
parental chromatids, carrying a duplication and a normal
Figure 3 Postzygotic hypothesis for the rearrangement in
chromosome 16 leading to genomic compensation in the
mother (II:3). Mitotic recombination between a paternal chromatid
carrying the duplication and a normal maternal chromatid during the
first zygotic divisions would originate four different chromatids, two of
which would be selected in a compensated genotype. Circles indicate
region 16p13.11, which is colored as in Figure 2. P and M designate
the paternal and maternal chromosome, respectively.
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carrying the two compensated non-sister chromatids in
the embryo, in a model similar to the one proposed by
Carelle-Calmels et al. [1] (Figure 3).
A consequence of postzygotic NAHR is chromosomal
mosaicism. Studies in the mother revealed the same
genotype in buccal swab and peripheral blood lympho-
cytes, suggesting that cell lineages with different genotypes
might have been restricted to other tissues or would have
been confined to extraembryonic tissues, a likely explan-
ation if the NAHR occurred in fact early after conception.
LCR-mediated NAHR may originate unstable products
that are more prone to act as substrates of new rear-
rangements in further generations [4]. In this case, it is
noteworthy that, considering the meiotic recombinations
observed in the grandparental gametes, both the proband’s
mother and maternal uncle received the same parental
genotypic contribution in 16p13.11, but the proposed
rearrangement occurred only in the mother (Figure 2).
This rearrangement resulted in gene dosage compensation,
preventing the possible phenotypic effects of the CNV in
that woman.
The phenotype of patients with 16p13.11 duplication
is very variable and it has been associated with clinical
features including behavioral abnormalities, autistic
spectrum disorders, congenital heart defects, skeletal
manifestations, and developmental delay [8]. Significant
association has been described for schizophrenia and
intellectual disability [13], and brain malformations have
been sporadically observed [14]. Psychomotor development
in the proband and his brother was normal at the time
of the assessment, although future cognitive handicap
cannot be ruled out. NDE1, one of the genes included
in the duplicated segment, is strongly expressed in brain,
and it forms complexes with LIS1, a dosage-sensitive gene
crucial for neuronal migration and cerebral development
[15] and known to underlie Miller–Dieker lissencephaly
syndrome (MIM 247200) [5]. Notwithstanding, since the
CNV is also present in other healthy family members, we
cannot associate it to the cerebral malformations observed
in the proband so it still remains as a finding of uncertain
significance.
On the other hand, this uncommon rearrangement in
chromosome 16 in the mother of the proband raises the
risk of an unbalanced pregnancy to 100%, since all of
Delicado et al. BMC Medical Genetics 2014, 15:116 Page 6 of 6
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or the deletion. The detection of this unusual rearrange-
ment emphasizes the need of parental FISH studies in
order to be able to offer accurate genetic counseling for
future pregnancies.
Conclusions
The increasing detection of these unusual rearrangements
reinforces the need to determine the genomic location
of interstitial gains or losses detected by aCGH [16].
Consequently, combined in situ hybridization and gen-
omic parental approaches are crucial in order to rule out
any balanced parental rearrangement that may involve a
very high recurrence risk.
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